Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FPC.0000000000000091PMID 25203738PMCID PMC4218879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis

  2014cited by this paper
• Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

  2013cited by this paper
• Expression analysis of MET, EGFR, and HER2, and K-ras mutation status in patients with stage II/III gastric cancer enrolled in the ACTS-GC study.

  2013cited by this paper
• A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population

  2012cited by this paper
• Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

  2012cited by this paper
• Influence of sex on the survival of patients with esophageal cancer.

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Association of Baseline Sex Hormone Levels with Baseline and Longitudinal Changes in Waist-to-Hip Ratio : Multi-Ethnic Study of Atherosclerosis

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Sex Hormones, Hormonal Interventions, and Gastric Cancer Risk: A Meta-analysis

  2011cited by this paper
• Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

  2011cited by this paper
• MET Expression and Amplification in Patients with Localized Gastric Cancer

  2011cited by this paper
• Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

  2011cited by this paper
• Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram

  2010cited by this paper
• MET signalling: principles and functions in development, organ regeneration and cancer

  2010cited by this paper
• Prognostic Role of Estrogen Receptor α and Estrogen Receptor β in Gastric Cancer

  2010cited by this paper
• Gender Disparities in Metastatic Colorectal Cancer Survival

  2009cited by this paper
• An integrative scoring system for ranking SNPs by their potential deleterious effects

  2009cited by this paper
• EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin.

  2009cited by this paper
• Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma

  2008cited by this paper
• HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

  2008cited by this paper
• Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women.

  2008cited by this paper
• Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study

  2008cited by this paper
• F-SNP: computationally predicted functional SNPs for disease association studies

  2007cited by this paper
• Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

  2007cited by this paper
• Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.

  2007cited by this paper
• Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?

  2006cited by this paper
• Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

  2006cited by this paper
• Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

  2005cited by this paper
• Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.

  2005cited by this paper
• Cancer therapy: can the challenge be MET?

  2005cited by this paper
• Wnt/β-Catenin and Estrogen Signaling Converge in Vivo*

  2004cited by this paper
• Wnt/beta-catenin and estrogen signaling converge in vivo.

  2004cited by this paper
• The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice.

  2003cited by this paper
• c-Met Expression in Gastric Cancer with Liver Metastasis

  2002cited by this paper
• Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling.

  2002cited by this paper
• Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  2000cited by this paper
• Tyrosine kinases and gastric cancer

  2000cited by this paper
• Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*

  2000cited by this paper
• Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer

  1999cited by this paper
• The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas

  1999cited by this paper
• Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization

  1999cited by this paper
• The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c‐met), autocrine motility factor receptor, and urokinase‐type plasminogen activator receptor

  1998cited by this paper
• Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2.

  1998cited by this paper
• Gene amplification in gastric and esophageal adenocarcinomas.

  1990cited by this paper

• Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study

  2019cites this paper
• OTT_A_189329 4195..4202

  2019cites this paper
• Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety

  2017cites this paper
• Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma

  2016cites this paper
• Immunoprofile of c-MET/PI3K signaling in human salivary gland tumors.

  2015cites this paper
• Clinical significance of MET in gastric cancer.

  2015cites this paper
• Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

  2015cites this paper
• Targeting the MET pathway for potential treatment of NSCLC

  2015cites this paper
• Association Analysis of MET Gene Polymorphism with Papillary Thyroid Carcinoma in a Chinese Population

  2015cites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper